API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
XP-8121 (levothyroxine) is a Investigational hormome, administered via Subcutaneous injection for the treatment of acquired thyroid disease.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: XP-8121
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
XP-8121 (levothyroxine) is a Investigational Subcutaneous injection thus indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary hypothyroidism),
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: XP-8121
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Levothyroxine sodium is a medicine used to treat an underactive thyroid gland (hypothyroidism). The thyroid gland makes thyroid hormones which help to control energy levels and growth. Levothyroxine is taken to replace the missing thyroid hormone thyroxine.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Rare Diseases and Disorders Product Name: Levothyroxine Sodium-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet therapies.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Tirosint
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mark Cuban Cost Plus Drug Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 07, 2023
Details:
XP-8121 (levothyroxine sodium) is administered when the body is deficient in the endogenous hormone and indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary hypothyroidism).
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: XP-8121
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
XP-8121 is a novel formulation that could potentially mitigate challenges linked to oral formulations, such as identification of an ideal dose due to absorption variation and medication adherence for patients who have difficulty maintaining a stable, therapeutic serum level.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: XP-8121
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2021
Details:
The study examined the potency and consistency of Tirosint-SOL marketed by IBSA Pharma Inc, using the same methodology as the previous study to determine the degree to which the product maintains its labeled potency over a five-week period.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Tirosint-SOL
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Thyquidity
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vertice Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Details:
The companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett to Commence Marketing on August 3, 2020.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cediprof
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 16, 2020